04:02 AM EST, 12/12/2024 (MT Newswires) -- HUTCHMED ( HCM ) said late Wednesday that China's National Medical Products Administration has granted breakthrough therapy designation to Orpathys in combination with Tagrisso to treat non-small cell lung cancer patients.

The designation qualifies the treatment candidate for a potential conditional approval and priority review, the company said.

The drug cocktail is currently being evaluated in a phase 3 trial in China.